MIR96-IN-1
目录号 : GC32929MIR96-IN-1选择性抑制微小RNA-96的生物合成,上调蛋白靶点(FOXO1)且诱导癌细胞凋亡。
Cas No.:1311982-88-3
Sample solution is provided at 25 µL, 10mM.
MIR96-IN-1 selectively inhibits biogenesis of microRNA-96, upregulating a protein target (FOXO1) and inducing apoptosis in cancer cells.Target: microRNA-96in vitro: MIR96-IN-1 inhibits biogenesis of its target precursor miRNA to varying extents : MIR96-IN-1 reduces the expression level of miR-96 by 90% at 40 μM. MIR96-IN-1 efficiently and selectively silences production of miR-96 at 40 μM while not affecting miR-182 or -183. Moreover, MIR96-IN-1 inhibits Drosha cleavage of pri-miR-96, as evidenced by an increase in the levels of pri-miR-96 and a reduction in levels of pre- and mature miR-96 in treated cells, as expected if MIR96-IN-1 binds to the Drosha site. [1]
[1]. Velagapudi SP, et al. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol. 2014 Apr;10(4):291-7. [2]. Haga CL, et al. Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling. ACS Chem Biol. 2015 Oct 16;10(10):2267-76. [3]. Velagapudi SP, et al. Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. J Am Chem Soc. 2011 Jul 6;133(26):10111-8.
Cas No. | 1311982-88-3 | SDF | |
Canonical SMILES | O=C(NCCCN=[N+]=[N-])CCCOC1=C(C(C)(C)C)C=C(C2=NC3=CC=C(N4CCN(C)CC4)C=C3N2)C=C1C(C)(C)C | ||
分子式 | C33H48N8O2 | 分子量 | 588.79 |
溶解度 | DMSO : ≥ 100 mg/mL (169.84 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6984 mL | 8.492 mL | 16.984 mL |
5 mM | 0.3397 mL | 1.6984 mL | 3.3968 mL |
10 mM | 0.1698 mL | 0.8492 mL | 1.6984 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet